评估费城急诊科出院后自动短信系统调查患者自报纳洛酮获取与携带情况
该队列研究在宾夕法尼亚州费城一家大型城市学术健康系统开展,纳入急诊处方或发放纳洛酮且有手机号的成年患者,2020年10月10日至2021年3月19日前瞻性通过自动短信调查患者自报纳洛酮获取、携带和使用情况。205例合格患者中41例(20.0%)完成调查,平均年龄39.5(13.7)岁,21例(51.2%)为女性;15例(36.6%)有因过量使用被给予纳洛酮的个人史。急诊记录显示27例(65.9%)在急诊发放纳洛酮,36例(87.8%)自报在急诊就诊期间或之后获取纳洛酮;24例(58.5%)在就诊前一周未携带纳洛酮,就诊后20例(48.8%)携带,27例(65.9%)计划未来继续携带。作者认为急诊仍是阿片类药物使用和过量高风险个体获取纳洛酮的关键场所,短信可能有助于激励患者自报行为。
要点
- 205例合格患者中仅41例(20.0%)完成短信调查,应答率低限制结果代表性。
- 41例完成调查者中36例(87.8%)自报在急诊就诊期间或之后获取纳洛酮,27例(65.9%)急诊记录显示在急诊发放。
- 就诊前一周24例(58.5%)未携带纳洛酮,就诊后20例(48.8%)携带,27例(65.9%)计划未来继续携带。
- 就诊前未携带的24例中13例(54.2%)计划未来继续携带纳洛酮。
- 15例(36.6%)有因过量使用被给予纳洛酮的个人史,提示该人群为过量高风险者。
适用人群与场景
- 在宾夕法尼亚州费城一家大型城市学术健康系统急诊就诊、被处方或发放纳洛酮、电子健康记录中登记有手机号的成年患者。
- 患者在急诊出院后提供知情同意,2020年10月10日至2021年3月19日前瞻性收集数据。
- 未回复调查或选择退出的患者被排除。
处置流程与药物剂量
- 急诊出院后对处方或发放纳洛酮的患者发送自动短信调查,评估自报纳洛酮获取、携带和使用情况。
研究设计与关键结果
- 研究类型为队列研究,在费城一家大型城市学术健康系统开展,205例合格患者中41例(20.0%)完成调查。
- 完成调查者平均(SD)年龄39.5(13.7)岁,21例(51.2%)为女性,15例(36.6%)有因过量使用被给予纳洛酮的个人史。
- 急诊记录显示27例(65.9%)在急诊发放纳洛酮,36例(87.8%)自报在急诊就诊期间或之后获取纳洛酮。
- 24例(58.5%)在急诊就诊前一周未携带纳洛酮,就诊后20例(48.8%)携带纳洛酮,27例(65.9%)报告计划未来继续携带纳洛酮。
- 就诊前未携带纳洛酮的24例中,13例(54.2%)报告计划未来继续携带纳洛酮。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为急诊仍是阿片类药物使用和过量高风险个体获取纳洛酮的关键场所。
- 作者认为短信可能是参与和激励患者自报行为、增强纳洛酮获取和携带的一种方法。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: A central tenet of harm reduction and prevention of opioid overdose deaths is the distribution and use of naloxone. Patient-centered methods that investigate naloxone acquisition and carrying can guide opioid overdose education and naloxone distribution efforts.
OBJECTIVE: To assess patients' self-reported naloxone acquisition and carrying after an emergency department (ED) encounter using automated text messaging.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study investigated self-reported patient behaviors involving naloxone after ED discharge in a large, urban academic health system in Philadelphia, Pennsylvania. Adult patients who were prescribed or dispensed naloxone and who had a mobile phone number listed in the electronic health record provided informed consent after ED discharge, and data were collected prospectively using text messaging from October 10, 2020, to March 19, 2021. Patients who did not respond to the survey or who opted out were excluded.
EXPOSURE: Automated text message-based survey after ED discharge for patients who were prescribed or dispensed naloxone.
MAIN OUTCOMES AND MEASURES: The primary outcome was patient-reported naloxone acquisition, carrying, and use. Descriptive statistics were used to summarize patient demographic characteristics.
RESULTS: Of 205 eligible patients, 41 (20.0%) completed the survey; of those patients, the mean (SD) age was 39.5 (13.7) years, and 21 (51.2%) were women. Fifteen (36.6%) had a personal history of being given naloxone after an overdose. As indicated by the ED record, 27 participants (65.9%) had naloxone dispensed in the ED, and 36 (87.8%) self-reported acquiring naloxone during or after their ED visit. Twenty-four participants (58.5%) were not carrying naloxone in the week before their ED visit. Twenty participants (48.8%) were carrying naloxone after the ED visit, and 27 (65.9%) reported planning to continue carrying naloxone in the future. Of the 24 individuals (58.5%) not carrying naloxone before their ED encounter, 13 (54.2%) reported planning to continue carrying naloxone in the future.
CONCLUSIONS AND RELEVANCE: In this cohort study of adult patients dispensed or prescribed naloxone from the ED, most reported acquiring naloxone on or after discharge. The ED remains a key point of access to naloxone for individuals at high risk of opioid use and overdose, and text messaging could be a method to engage and motivate patient-reported behaviors in enhancing naloxone acquisition and carrying.
参考来源
- Agarwal AK, Sangha HK, Spadaro A, et al. Assessment of Patient-Reported Naloxone Acquisition and Carrying With an Automated Text Messaging System After Emergency Department Discharge in Philadelphia. JAMA Netw Open. 2022. PMID: 35323949. doi:10.1001/jamanetworkopen.2022.3986
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。